Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019
Published By : SA-BRC Published Date : 2015-06-01 Category : Pharmaceutical & Healthcare Sub Category : Pharmaceutical No. of Pages : 56

North American anti-bacterial drugs market is valued at US$ 17,079.8 million for 2015 according to the new report “Global Anti-Bacterial Drugs Market Assessment, Forecast: 2015 - 2019” by SA-Business Research & Consulting group.

North America continued to lead global anti-bacterial drugs market with a share of 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempra, Actelion, Achaogen and Melinta. Europe and Asia-Pacific followed with market shares of 24.7% and 18.7% respectively. Asia-Pacific is expected to overtake Europe with expirations of several drugs that will be absorbed by the strong generics market by the end of this decade. China remains the largest supplier of raw materials and active moiety to drug manufacturers over the world. With emerging countries such as India and China, the Asia-Pacific region is expected to remain a major threat to innovators and originator companies developing new drugs.

In light of the recent violent clashes throughout different regions of Europe and unpredicted future in conflict regions such as Ukraine and Syria have taken considerable toll in investments for healthcare and progress. There are several initiatives that continue to support the development such as the New Drugs for Bad Bugs (ND4BB) initiative and the IMI-funded COMBACTE project, which aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing efficient clinical trials for novel antibiotics. These initiatives will drive the innovation of the drugs market in coming years. Price fixing also tends to restrict revenues in the region and other challenges include regulatory hurdles such that new drugs need to show non-inferiority in clinical trials within a margin of 10% as compared with current gold standards.

Aging population, hospital and community acquired infections are major drivers for the growth of the market whereas regulatory hurdles and uncertain drug resistance qualities in microbes continue to plague the growth of the market. With a small number of pipeline drugs currently being developed, the anti-bacterials market for western regions that contribute mainly towards branded drugs will be in jeopardy by the end of this decade. By 2030, Asia will have almost 700 million people aged over 60 and largest middle aged population. The region exports over 75% of all global generics and its revenues account 65% for generics and remaining for brands. Ventilator associated and community associated pneumonia along with other diseases have been creating a serious impact on the healthcare system in Asia. Most developing countries have limited resources and hospital facilities to carry out fully functional and sterile conditions that have increased incidences. Improving economic scenario and healthcare infrastructure is expected to drive innovation and create greater opportunities in coming years.

Chapter 1 Preface
1.1 Research Scope
1.1.1 Market Segmentation
1.1.2 Postulations
1.2 Methodology of Research
1.2.1 Companies covered in this report
Chapter 2 Précis
2.1 Market Inferences
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Increasing incidence of hospital and community acquired bacterial infections pushing growth of brands and generics
3.1.2 Improving Legal Framework for provision of Incentives expected to drive growth
3.2 Market Inhibitors
3.2.1 Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics
3.3 Opportunities
3.3.1 R&D in treatment of carbapenem-resistant enterobacteria will open new market
3.3.2 Existence of Considerable Target Population in Emerging Economies
Chapter 4 Global Anti-Bacterial Drugs Market Assessment, by Current Marketed Brands - Size & Forecast, 2015 – 2019 (US$ Millions)
4.1 Introduction
4.2 Cubicin (daptomycin) Market, US$ Mn (2013 - 2019)
4.3 Teflaro/Zinforo (ceftaroline) Market, US$ Mn (2013 - 2019)
4.4 Dificid (fidaxomicin) Market, US$ Mn (2013 - 2019)
4.5 Dalvance (dalbavancin) Market, US$ Mn (2013 - 2019)
4.6 Orbactiv (oritavancin) Market, US$ Mn (2013 - 2019)
4.7 Sivextro (tedizolid) Market, US$ Mn (2013 - 2019)
4.8 Zerbaxa (ceftolozane + tazobactam) Market, US$ Mn (2013 - 2019)
4.9 Avycaz (ceftazidime-avibactam) Market, US$ Mn (2013 - 2019)
4.10 Zyvox (linezolid) Market, US$ Mn (2013 - 2019)
4.11 Avelox (moxifloxacin) Market, US$ Mn (2013 - 2019)
4.12 Augmentin (amoxicillin + clavulanic acid) Market, US$ Mn (2013 - 2019)
4.13 Zosyn/Tazocin (piperacillin + tazobactam) Market, US$ Mn (2013 - 2019)
4.14 Invanz (ertapenem) Market, US$ Mn (2013 - 2019)
4.15 Tygacil (tigecyline) Market, US$ Mn (2013 - 2019)
4.16 Other Prominent Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
Chapter 5 Global Anti-Bacterial Drugs Market Assessment for Pipeline Drugs - Size & Forecast, 2015 – 2019 (US$ Millions)
5.1 Introduction
5.2 Surotomycin Market, US$ Mn (2013 - 2019)
5.3 Solitaire (solithromycin) Market, US$ Mn (2013 - 2019)
5.4 Delafloxacin Market, US$ Mn (2013 - 2019)
5.5 Plazomycin Market, US$ Mn (2013 - 2019)
5.6 Taksta (fusidic acid) Market, US$ Mn (2013 - 2019)
5.7 Cadazolid Market, US$ Mn (2013 - 2019)
5.8 Carbavance Market, US$ Mn (2013 - 2019)
5.9 Eravacycline Market, US$ Mn (2013 - 2019)
5.10 Other Early-Stage Anti-Bacterial Candidates
5.10.1 Finafloxacin
5.10.2 Omadacycline
5.10.3 Zabofloxacin
5.10.4 Ramoplanin
5.10.5 Nemonoxacin
5.10.6 Relebactam (MK-7655)
Chapter 6 Global Anti-Bacterial Drugs Market Assessment –Size & Forecast, By Geography, 2015 – 2019 (US$ Millions)
6.1 Introduction
6.2 North America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.3 Europe Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.4 Asia-Pacific Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.5 Latin America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.6 Middle-East Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
6.7 Africa Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019)
Chapter 7 Key Players Analysis: Global Anti-Bacterial Drugs Market, 2014 (%)
7.1 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)
7.2 Global Anti-Bacterial Drugs Market: Recent Developments 2013-2015
7.2.1 Mergers and Acquisitions
7.2.2 New Product Launches and Approvals
7.3 Competitive Landscape: Strategies
Chapter 8 Epilogue


List of Figures

FIG. 1 Market Segmentation: Anti-Bacterial Drugs Market Assessment & Forecast (2015-2019)
FIG. 2 Research Methodology: Global Anti-Bacterial Drugs Market Assessment
FIG. 3 Global Anti-Bacterial Drugs Market Share, by Geography 2014 & 2019 (% Share - US$ Million)
FIG. 4 Global Anti-Bacterial Drugs Market – Cubicin (daptomycin) Revenues 2013 – 2019 (US$ Millions)
FIG. 5 Global Anti-Bacterial Drugs Market – Teflaro/Zinforo (ceftaroline) Revenues 2013 – 2019 (US$ Millions)
FIG. 6 Global Anti-Bacterial Drugs Market – Dificid (fidaxomicin) Revenues 2013 – 2019 (US$ Millions)
FIG. 7 Global Anti-Bacterial Drugs Market – Dalvance (dalbavancin) Revenues 2013 – 2019 (US$ Millions)
FIG. 8 Global Anti-Bacterial Drugs Market – Orbactiv (oritavancin) Revenues 2013 – 2019 (US$ Millions)
FIG. 9 Global Anti-Bacterial Drugs Market – Sivextro (tedizolid-phosphate) Revenues 2013 – 2019 (US$ Millions)
FIG. 10 Global Anti-Bacterial Drugs Market – Zerbaxa (ceftolozane + tazobactam) Revenues 2013 – 2019 (US$ Millions)
FIG. 11 Global Anti-Bacterial Drugs Market – Avycaz (ceftazidime-avibactam) Revenues 2013 – 2019 (US$ Millions)
FIG. 12 Global Anti-Bacterial Drugs Market – Zyvox (linezolid) Revenues 2013 – 2019 (US$ Millions)
FIG. 13 Global Anti-Bacterial Drugs Market – Avelox (moxifloxacin) Revenues 2013 – 2019 (US$ Millions)
FIG. 14 Global Anti-Bacterial Drugs Market – Augmentin (amoxicillin + clavulanic acid) Revenues 2013 – 2019 (US$ Millions)
FIG. 15 Global Anti-Bacterial Drugs Market – Zosyn/Tazocin (piperacillin + tazobactam) Revenues 2013 – 2019 (US$ Millions)
FIG. 16 Global Anti-Bacterial Drugs Market – Invanz (ertapenem) Revenues 2013 – 2019 (US$ Millions)
FIG. 17 Global Anti-Bacterial Drugs Market – Tygacil (tigecyline) Revenues 2013 – 2019 (US$ Millions)
FIG. 18 Global Anti-Bacterial Drugs Market – Other Anti-Bacterial Drug Revenues 2013 – 2019 (US$ Millions)
FIG. 19 Global Anti-Bacterial Drugs Market – Surotomycin Revenues 2013 – 2019 (US$ Millions)
FIG. 20 Global Anti-Bacterial Drugs Market – Solitaire (solithromycin) Revenues 2013 – 2019 (US$ Millions)
FIG. 21 Global Anti-Bacterial Drugs Market – Delafloxacin Revenues 2013 – 2019 (US$ Millions)
FIG. 22 Global Anti-Bacterial Drugs Market – Plazomycin Revenues 2013 – 2019 (US$ Millions)
FIG. 23 Global Anti-Bacterial Drugs Market – Taksta Revenues 2013 – 2019 (US$ Millions)
FIG. 24 Global Anti-Bacterial Drugs Market – Cadazolid Revenues 2013 – 2019 (US$ Millions)
FIG. 25 Global Anti-Bacterial Drugs Market – Carbavance Revenues 2013 – 2019 (US$ Millions)
FIG. 26 Global Anti-Bacterial Drugs Market – Eravacycline Revenues 2013 – 2019 (US$ Millions)
FIG. 27 North America Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 28 Europe Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 29 Asia-Pacific Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 30 Latin-America Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 31 Middle-East Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 32 Africa Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions)
FIG. 33 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%)


List of Tables

TABLE 1 List of companies covered in this report
TABLE 2 Global Anti-Bacterial Drugs Market, by Geography, 2013 - 2019 (US$ Mn) (CAGR: 2015 - 2019)